Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Guardant Health (NASDAQ:GH) but lowered the price target from $52 to $45.
October 23, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Guardant Health but lowered the price target from $52 to $45.
The news is directly related to Guardant Health. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100